Current Therapy in CKD Patients Can Affect Vitamin K Status

Area of Science:

• Nephrology
• Cardiology
• Nutritional Science

Background:

• Chronic kidney disease (CKD) elevates cardiovascular disease (CVD) risk.
• CKD-MBD involves mineral and bone metabolism abnormalities, including vascular calcification.
• Subclinical vitamin K deficiency is increasingly recognized in CKD patients.

Purpose of the Study:

• To explore the role of vitamin K deficiency in CKD-associated bone and vascular complications.
• To hypothesize vitamin K deficiency as a common link between impaired bone mineralization and vascular calcification.
• To investigate how common CKD treatments may affect vitamin K metabolism.

Main Methods:

• Review of existing literature on CKD, CVD, CKD-MBD, and vitamin K metabolism.
• Analysis of the impact of nutritional restrictions, warfarin, VDRA, calcimimetics, and phosphate binders on vitamin K status.
• Hypothetical modeling of vitamin K's role in CKD pathophysiology.

Main Results:

• Vitamin K is crucial for proteins involved in bone and vascular health.
• Several common CKD management strategies may negatively impact vitamin K levels.
• Vitamin K deficiency presents a potential therapeutic target in CKD.

Conclusions:

• Vitamin K deficiency may be a unifying factor in CKD-related bone and vascular issues.
• CKD treatments require careful consideration regarding their effects on vitamin K status.
• Further research is warranted to confirm vitamin K's therapeutic potential in CKD.